The Association between Circulating Cytokines and Body Composition in Frail Patients with Cardiovascular Disease.
Ilona Korzonek-SzlachetaBartosz HudzikBarbara Zubelewicz-SzkodzinskaZenon Paweł CzubaPatryk SzlachetaAndrzej TomasikPublished in: Nutrients (2024)
The burden of cardiovascular disease and the percentage of frail patients in the aging population will increase. This study aims to assess the circulating levels of several cytokines in frail patients. This is an ancillary analysis of the FRAPICA trial. The ratio of men/women changed from robust through frail groups from 3:1 to 1:2. The groups are comparable in terms of age and body measurements analysis (weight, height, and BMI), yet the frail patients have significantly reduced fat-free mass, and more often have been diagnosed with diabetes. Frail patients have higher fibroblast growth factor basic (FGF basic) and follistatin levels (borderline significance). In multiple linear regression modeling of fat-free mass, we identified FGF basic, osteopontin, stem cell factor, soluble suppression of tumorigenicity 2, soluble epidermal growth factor receptor, soluble human epidermal growth factor receptor 2, follistatin, prolactin, soluble interleukin 6 receptor alfa, platelet endothelial cell adhesion molecule 1, soluble vascular endothelial cell growth factor receptor 1, leptin, soluble angiopoietin/tyrosine kinase 2, and granulocyte colony-stimulating factor. We have identified a few cytokines that correlate with fat-free mass, a hallmark of frailty. They comprise the kinins implicated in bone and muscle metabolism, fibrosis, vascular wall function, inflammation, endocrine function, or regulation of bone marrow integrity.
Keyphrases
- epidermal growth factor receptor
- cardiovascular disease
- end stage renal disease
- tyrosine kinase
- newly diagnosed
- body composition
- ejection fraction
- stem cells
- chronic kidney disease
- bone marrow
- growth factor
- type diabetes
- prognostic factors
- body mass index
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- oxidative stress
- mesenchymal stem cells
- patient reported outcomes
- pregnant women
- open label
- high intensity
- data analysis
- glycemic control
- weight gain
- bone regeneration
- breast cancer risk